skip to content
Primary navigation


DrugsBasaglar (insulin glargine) [Eli Lilly and Company]

June 2017

Therapeutic area - Insulin

Approval criteria

  • Patient is allergic to Lantus OR
  • Patient has an inadequate response to Lantus but has had a demonstrated adequate response to the Basaglar OR
  • Patient is unable to change to Lantus due to a cognitive or developmental disability OR
  • Changing to Lantus would create undue hardship for the patient

Quantity limits

90 mL per 34 days

Background information

Basaglar is approved by the FDA under the New Drug Application (NDA) pathway and is not considered an interchangeable biosimilar to Lantus. Basaglar is a long-acting human insulin analog, with an identical amino acid sequence to Lantus, indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top